Taurohyodeoxycholic acid (sodium)

Taurohyodeoxycholic acid (THDCA) sodium is the taurine-conjugated form of the secondary bile acid hyodeoxycholic acid. Taurohyodeoxycholic acid can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model.

Product Specifications

CAS Number

[38411-85-7]

UNSPSC

12352200

Hazard Statement

H302, H315, H319, H335

Target

Interleukin Related; TNF Receptor

Type

Biochemical Assay Reagents

Related Pathways

Apoptosis; Immunology/Inflammation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/taurohyodeoxycholic-acid-sodium.html

Purity

99.60

Solubility

H2O : 62.5 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@]3([H])[C@](C[C@@H]([C@]1([H])C[C@@H](CC2)O)O)([H])[C@@]4([H])[C@](CC3)([C@@](CC4)([H])[C@H](C)CCC(NCCS(=O)(O[Na])=O)=O)C

Molecular Formula

C26H44NNaO6S

Molecular Weight

521.69

Precautions

H302, H315, H319, H335

References & Citations

[1]Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27 (2) :520-5. |[2]Angelico M, et al. Dissolution of human cholesterol gallstones in bile salt/lecithin mixtures: effect of bile salt hydrophobicity and various pHs. Scand J Gastroenterol. 1995 Dec;30 (12) :1178-85. |[3]Angelico M, et al. Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat. Dig Dis Sci. 1994 Nov;39 (11) :2389-97. |[4]Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27 (2) :520-5. |[5]Solmon Kusuma S, et al. Antineoplastic activity of monocrotaline against hepatocellular carcinoma[J]. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2014, 14 (9) : 1237-1248.